Abiopharma

🔍 Fenton Mary Kay (Executive)

Company: Cullinan Therapeutics, Inc. (CGEM)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 27 shares of Common Stock at $6.49 per share (Direct)
  Date: 2025-12-31 | Code: A | equity_swap_involved: false | shares_owned_after: 62,028.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3

Footnotes:

• F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2021 Employee Stock Purchase Plan (the "ESPP"), for the purchase period of July 1, 2025 through December 31, 2025. This transaction is also exempt under Rule 16b-3(c).
• F2: In accordance with the ESPP, the shares were purchased based on 85% of the closing price of the Issuer's common stock on July 1, 2025.
• F3: Includes 2,001 shares of common stock that the Reporting Person purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan for the purchase period of January 1, 2025 through June 30, 2025 that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).